Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892462 · ClinicalTrials.gov registry record
Circulating Biomarkers and Ventricular Tachyarrhythmia
A clinical trial, sponsored by Ochsner Health System.
- Completed
- Registry status
- 220
- Enrollment target
NCT01892462: Completed study, sponsored by Ochsner Health System.
NCT01892462 is a clinical trial that has completed, run by Ochsner Health System. The registered enrollment target is 220 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01892462 has completed, sponsored by Ochsner Health System.
- COMPLETED
- Registry status
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether levels of inflammatory markers in circulating blood can correlate with risk for dangerous heart rhythms. Patients with systolic heart failure, which has been shown to increase risk for dangerous heart rhythms, will be enrolled. All subjects will have an implantable cardioverter-defibrillator (ICD) in place, which allows regular evaluation of heart rhythm.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-10 |
What the finished NCT01892462 record still lists
NCT01892462 is an observational study that tracks outcomes without assigning an intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01892462 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01892462 about?
NCT01892462 is a clinical study titled "Circulating Biomarkers and Ventricular Tachyarrhythmia". The purpose of this study is to determine whether levels of inflammatory markers in circulating blood can correlate with risk for dangerous heart rhythms. Patients with systolic heart failure, which has been shown to increase risk for dangerous heart rhythms, will be enrolled. All subjects will have...
What is the current status of trial NCT01892462?
This trial is currently completed. The enrollment target is 220 participants. The study started on 2012-06. Estimated completion is 2016-10.
Who is sponsoring clinical trial NCT01892462?
This trial is sponsored by Ochsner Health System, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia